Literature DB >> 8603987

Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms.

J C Lee1, P R Young.   

Abstract

A new member of the mitogen-activated protein kinase family, alternatively termed CSBP, p38, or RK, has been identified independently by several laboratories recently. Activation of this novel protein kinase via dual phosphorylation has been observed in different cell systems upon stimulation by a wide spectrum of stimuli, such as physicochemical stress and treatment with lipopolysaccharide or proinflammatory cytokines such as interleukin-1 and tumor necrosis factor. Furthermore, CSAID cytokine biosynthesis inhibitors have now been determined to be potent and selective inhibitors of CSBP/p38/RK kinase activity. These inhibitors will help to dissect signaling pathways involved in inflammatory responses. In particular, for the first time a definitive signal transduction pathway can be prescribed to the action of lipopolysaccharide in cytokine production in macrophages.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603987     DOI: 10.1002/jlb.59.2.152

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  76 in total

Review 1.  Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation.

Authors:  J Berkes; V K Viswanathan; S D Savkovic; G Hecht
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

2.  Posttranscriptional regulation of IL-23 expression by IFN-gamma through tristetraprolin.

Authors:  Xuesong Qian; Huan Ning; Jidong Zhang; Daniel F Hoft; Deborah J Stumpo; Perry J Blackshear; Jianguo Liu
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

Review 3.  Signaling through the P38 and ERK pathways: a common link between HIV replication and the immune response.

Authors:  Robert L Furler; Christel H Uittenbogaart
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

4.  Phosphorylation and function of the kaposin B direct repeats of Kaposi's sarcoma-associated herpesvirus.

Authors:  Craig McCormick; Don Ganem
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway.

Authors:  M Rincón; H Enslen; J Raingeaud; M Recht; T Zapton; M S Su; L A Penix; R J Davis; R A Flavell
Journal:  EMBO J       Date:  1998-05-15       Impact factor: 11.598

6.  Effect of the p38 kinase inhibitor, SB 203580, on allergic airway inflammation in the rat.

Authors:  K J Escott; M G Belvisi; M A Birrell; S E Webber; M L Foster; C A Sargent
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

7.  Induction of adhesion molecule expression in co-culture of human bronchial epithelial cells and neutrophils suppressed by puerarin via down-regulating p38 mitogen-activated protein kinase and nuclear factor κB pathways.

Authors:  Ye Liu; Ling-li Shao; Wei Pang; Xiao-mei Lan; Jian-xin Lu; Yu-long Cong; Cheng-bin Wang
Journal:  Chin J Integr Med       Date:  2014-05       Impact factor: 1.978

8.  Tyrosine 763 of the murine granulocyte colony-stimulating factor receptor mediates Ras-dependent activation of the JNK/SAPK mitogen-activated protein kinase pathway.

Authors:  O Rausch; C J Marshall
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

9.  Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.

Authors:  Hew Yeng Lai; Stefan A Brooks; Brianna M Craver; Sarah J Morse; Thanh Kim Nguyen; Nahideh Haghighi; Michael R Garbati; Angela G Fleischman
Journal:  Blood Adv       Date:  2019-01-22

10.  Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists.

Authors:  Elena Riboldi; Giada Frascaroli; Pietro Transidico; Walter Luini; Sergio Bernasconi; Francesca Mancini; Angelo Guglielmotti; Claudio Milanese; Mario Pinza; Silvano Sozzani; Alberto Mantovani
Journal:  Br J Pharmacol       Date:  2003-08-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.